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2Summary
The ability of vertebrates to detect and avoid damaging extremes of temperature depends on 
activation of ion channels belonging to the thermo-TRP family. Injury or inflammation 
lowers the threshold for detection of painful levels of heat, a process known as heat 
hyperalgesia. A wide range of inflammatory mediators is able to promote heat hyperalgesia, 
and these activate at least three distinct intracellular signalling pathways which lower the 
threshold of the heat-activated ion channel TRPV1. Here we show that modulation of the 
sensitivity of TRPV1 by the protein kinases PKA and PKC, and by the phosphatase 
calcineurin, depends on the formation of a signalling complex between the scaffolding 
protein AKAP79/150 and TRPV1. We identify a critical region in the TRPV1 C-terminal 
which mediates binding of AKAP79/150. If binding is prevented then sensitisation by both 
bradykinin and PGE2 is abrogated. AKAP79/150 is therefore a final common element in heat 
hyperalgesia, on which the effects of multiple pro-inflammatory mediators converge.
3Introduction
Animals detect thermal stimuli via the activation of primary sensory nerve terminals
responding to a range of temperatures from noxious cold, through the non-noxious range, and 
extending to damaging extremes of heat  (Darian-Smith, 1984; Perl, 1984; Lumpkin and 
Caterina, 2007). Thermal stimuli activate inward membrane currents in temperature-sensitive 
neurons  (Cesare and McNaughton, 1996; Reid and Flonta, 2001), and they do so by the 
direct activation of temperature-sensitive ion channels belonging to the thermo-TRP family 
(Jordt et al., 2003; Venkatachalam and Montell, 2007; Nilius et al., 2007). The best-studied 
thermo-TRPs are as follows: TRPV1, which is activated by noxious temperatures above 43C 
(Caterina et al., 1997); TRPV2, activated by higher temperatures, above 52C (Caterina et al., 
1999); TRPV3 and TRPV4, activated in the range of non-noxious warmth, c. 35- 37C 
(Smith et al., 2002; Xu et al., 2002; Guler et al., 2002; Watanabe et al., 2002); TRPM8, 
activated by cooling below c. 30C (McKemy et al., 2002); and TRPA1, which may be 
activated by more extreme cooling (Story et al., 2003), though other recent studies have 
failed to confirm the activation of this ion channel by cold (Bautista et al., 2006).
The temperature thresholds of thermally activated ion channels are modulated by a 
range of extracellular factors (Huang et al., 2006; Venkatachalam and Montell, 2007). The 
temperature threshold of TRPV1 is lowered by a wide range of pro-inflammatory mediators 
such as bradykinin, prostaglandin E2 (PGE2) and nerve growth factor (NGF). The lowering of 
the TRPV1 threshold is critical for heat hyperalgesia, the process by which the threshold for 
heat pain is lowered following inflammation or injury, because heat hyperalgesia is ablated 
when TRPV1 is genetically deleted (Davis et al., 2000; Caterina et al., 2000). 
Three pathways are known to lead to sensitization of TRPV1. The activation of the Gq-
coupled B1 and B2 receptors by bradykinin lowers the temperature threshold of TRPV1 by 
promoting phosphorylation by PKCε  (Cesare and McNaughton, 1996; Cesare et al., 1999; 
Numazaki et al., 2002; Bhave et al., 2003). An alternative possibility, that metabolism of PIP2
4by PLCβ may release TRPV1 from PIP2-mediated inhibition (Chuang et al., 2001), is not 
supported by more recent evidence showing that PIP2 in fact activates rather than inhibiting 
TRPV1 (Stein et al., 2006; Lishko et al., 2007). In sensory neurons PGE2 activates the EP4
receptor, which is Gs–coupled and causes sensitization by promoting PKA-dependent 
phosphorylation of TRPV1  (Bhave et al., 2002; Distler et al., 2003). In a third pathway 
leading to sensitization of TRPV1, NGF potentiates TRPV1 by activating  PI3 kinase and the 
tyrosine kinase Src, leading to phosphorylation of TRPV1 at Y200 and to promotion of 
trafficking of TRPV1 to the neuronal cell membrane (Zhang et al., 2005; Stein et al., 2006). 
A proposal that NGF sensitizes TRPV1 by activating PLC and thus reducing levels of PIP2
(Chuang et al., 2001; Prescott and Julius, 2003) is not supported by more recent evidence 
(Zhang et al., 2005).
The speed and specificity of the action of kinases is in many cases enhanced by the use 
of scaffolding proteins which pre-assemble the kinases into signalling complexes with their 
substrates.  The AKAP (A Kinase Anchoring Protein) family of scaffolding proteins were 
originally named for their ability to target PKA to appropriate substrates, but are now known 
to assemble a wide range of kinases and phosphatases into signalling complexes with 
appropriate targets  (Leiser et al., 1986; Bregman et al., 1989; reviewed by Smith et al., 
2006).  AKAP79/150 targets PKA, PKC and the Ca-dependent phosphatase calcineurin to 
appropriate substrates (Coghlan et al., 1995; Klauck et al., 1996). AKAP79 is the human 
homolog, while AKAP150, the mouse homolog, seems to be similar in function to AKAP79 
but contains an additional large central domain. 
A number of ion channels are subject to modulation by AKAPs, including glutamate 
receptors, calcium channels and M-type potassium channels  (Gao et al., 1997; Colledge et 
al., 2000; Altier et al., 2002; Hoshi et al., 2003; Hoshi et al., 2005; Sandoz et al., 2006; 
Oliveria et al., 2007; Lu et al., 2007; Chai et al., 2007; Navedo et al., 2008). An AKAP may 
be involved in the modulation of TRPV1 by PKA (Rathee et al., 2002; Distler et al., 2003) 
but neither the AKAP family member involved nor its binding site on TRPV1 have been 
5identified, and the possibility that other kinases such as PKC and Src may also be assembled 
into a functional signalling complex important in the regulation of TRPV1 has not been 
explored. These questions are addressed in the present paper.
6Results 
Co-expression of AKAP79/150 and TRPV1 in sensory neurons
Several AKAPs are expressed in sensory neurons, amongst them AKAP79/150 (Rathee 
et al., 2002). Fig. 1A shows that the vast majority of rat DRG neurons which express TRPV1 
(left panel) also express AKAP150 (centre panel and merged image in right panel). We found 
that 91.1  1.7 % of neurons expressing TRPV1 also expressed AKAP150 (n=352). Evidence 
for a physical association between the two in sensory neurons was obtained in co-
immunoprecipitation experiments in which pull-down of TRPV1, using an antibody raised to 
the TRPV1 N-terminal domain, also brought down AKAP150 (Fig. 1B).
In later experiments in this study it was important to be able to manipulate endogenous 
AKAP79/150 levels in both DRG neurons and in a HEK293 expression system. We 
constructed an siRNA against AKAP150 and AKAP79, as used by Hoshi et al  (2005) but in 
a vector which co-expresses GFP to enable identification of successfully transfected cells. 
The siRNA against AKAP150 reduced expression levels in transfected rat DRG neurons to 
12.1 ± 1.9% of control (Fig. 1C, n=6), and the siRNA against AKAP79 reduced expression in 
HEK293 cells to 15.9 ± 2.6% of control (Fig. 1D, n =22). A similar but lesser downregulation 
was seen in Western blots of HEK293 cell protein (Fig. 1E, 30.4 ± 2.5% of control, n=3), a 
difference which is expected because not all cells are transfected. In all cases a scrambled 
siRNA with the same base composition was completely ineffective (Fig. 1C-E).
Binding of AKAP79 to thermo-TRPs
The experiments in Fig. 2 show that AKAP79 expressed in HEK293 cells binds to 
several members of the thermo-TRP family of ion channels. AKAP79 expressed in HEK293 
cells co-immunoprecipitates with several thermo-TRPs (Fig. 2A), particularly with TRPV1 
and TRPV4, and to a lesser extent TRPM8 and TRPA1. Endogenous AKAP79 can also co-
immunoprecipitate lesser amounts of TRPV1 (Fig. 1B, top left panel). Fig. 2C shows that the 
7binding between TRPV1 and AKAP79 does not depend on the use of the V5 tag attached to 
the C-terminal as it is also observed when an antibody raised to the N-terminal TRPV1 
domain is used.
We next localised the TRPV1 binding site for AKAP79 by constructing GST-coupled 
fragments of the four intracellular domains of TRPV1, expressed in bacteria, and exploring 
binding to AKAP79 in vitro. The major binding domain is in the C-terminal portion of 
TRPV1 (Fig. 2D), with only weak binding observed to the large N-terminal domain and no 
detectable binding to either of the intracellular loops. When the GST-coupled C-terminal 
domain was progressively truncated there was an increase in binding on removal of the 
region between amino acids 759 and 777, probably because of removal of an inhibitory 
region, but more significantly there was a substantial loss of binding on removal of amino 
acids 736 to 749 (Fig. 2E, left panel; note that all residue numbering is for hTRPV1). 
Deletion of just this region caused a major reduction in binding, while other nearby deletions 
were much less effective (Fig. 2E, right panel). We repeated this deletion in intact TRPV1, 
expressed in HEK293 cells,  and found that removal of this region also caused a substantial 
reduction in the binding of AKAP79 to intact TRPV1 (Supplementary Fig. 1A). We next 
constructed a 14aa peptide, identical to this binding domain, which should be able to compete 
for the site on AKAP79 to which TRPV1 binds. At a concentration of 200µM this peptide 
largely prevented binding of AKAP79 to the GST-coupled C-terminal fragment of TRPV1, 
while a scrambled peptide of the same composition was ineffective (Fig. 2F). The peptide 
was also highly effective in displacing AKAP79 from binding to intact TRPV1 (Fig. 2G).
AKAP79/150 promotes activation of TRPV1
We found that expression of AKAP79 enhanced the sensitivity of TRPV1 to capsaicin 
even in the absence of overt activation of PKC or PKA by pro-inflammatory mediators (Fig. 
3A, compare red points and curve with black points and curve). Conversely, expression of 
8AKAP79 with the PKC binding site deleted (Hoshi et al., 2005) reduced the sensitivity of 
TRPV1 (green points and curve). The fact that AKAP79 can enhance sensitivity, while 
deletion of the PKC binding site on AKAP79 has a dominant negative effect, shows the 
phosphorylation by PKC is important in modulating sensitivity of TRPV1 even in the resting 
cell. The results also show that endogenous AKAP79 does not saturate its binding sites on 
TRPV1, because overexpression of AKAP79 has an effect greater than that of endogenous 
AKAP79. 
Deletion of the PKA binding site had a smaller effect than deletion of the PKC site 
(grey squares), showing that phosphorylation by constitutively active PKA is less important 
than PKC in the resting cell. The effect of expression of an AKAP79 with the calcineurin 
(PP2B) binding site deleted was indistinguishable from that of wild-type AKAP79 (blue 
points), suggesting that calcineurin bound to AKAP79 makes little contribution to 
dephosphorylating TRPV1 at resting levels of calcium. 
TRPV1 ion channels can be opened even in the absence of agonist by strong membrane 
depolarisation  (Voets et al., 2004). Activation of PKC potentiates this process by enabling 
opening of TRPV1 at lower membrane potentials  (Matta and Ahern, 2007), and our 
demonstration that AKAP79 is involved in potentiation of TRPV1 by PKC suggests that it 
will have a similar effect. Fig. 3B shows that activating PKC or overexpressing AKAP79 
both have similar effects in potentiating the opening of TRPV1 by membrane depolarisation, 
and moreover that the actions are to some extent additive. Fig. 3C and D demonstrate that 
overexpression of AKAP79 shifts the voltage activation curve to less depolarised potentials 
by 54mV, and that subsequent full activation of PKC causes an additional 32mV negative 
shift. In summary, the experiments in Fig. 3 show that expression of AKAP79 promotes 
activation of TRPV1 by both capsaicin and membrane potential, and moreover that this 
action depends mainly on the binding of PKC to AKAP79.
9AKAP79/150 is essential for sensitization of TRPV1via PKC and PKA pathways
We next investigated whether AKAP79/150 mediates the sensitization of TRPV1 
caused by pro-inflammatory mediators. For these experiments we used a low dose of 
capsaicin as a convenient activator of TRPV1, because the sensitivity of TRPV1 to heat, 
capsaicin, low pH and a range of other activators is known to be enhanced in a similar way 
by pro-inflammatory mediators (Vellani et al., 2001). 
In rat sensory neurons bradykinin caused a substantial enhancement of the inward 
current mediated by TRPV1 (Fig. 4A), a process which has been shown to be due to 
phosphorylation of serines 502 and 801 by PKCε  (Cesare and McNaughton, 1996; Cesare et 
al., 1999; Numazaki et al., 2002; Bhave et al., 2003). Incorporation of the 14aa peptide which 
prevents binding of AKAP150 to TRPV1 completely inhibited sensitization by Bk, while the 
scrambled peptide was ineffective (Fig. 4A, B). An alternative way of demonstrating an 
involvement of AKAP150 is to downregulate endogenous expression using siRNA. Fig 4A 
and B show that removal of AKAP150 in this way almost completely inhibited the action of 
Bk in sensory neurons, while a scrambled siRNA was ineffective. Finally, simultaneously 
transfecting with AKAP79, which is insensitive to the siRNA against AKAP150  (Hoshi et 
al., 2005), rescued the sensitization by BK, and in fact the overexpression of AKAP79 causes 
an enhanced level of sensitization (final bar, Fig. 4B). 
Bradykinin also caused a substantial sensitization of TRPV1 in HEK293 cells 
transfected with the Gq-coupled B2 receptor (Fig. 4C). Sensitization was abolished by 
deletion of the PKC binding site on AKAP79, by downregulation of endogenous AKAP79 
with siRNA, or by mutation of the S502 and S801 sites on TRPV1, which are known targets 
for phosphorylation by PKC (Numazaki et al., 2002; Bhave et al., 2003); see Fig. 4D. 
Deletion of the PKA binding site, however, had a lesser effect than deletion of the PKC site 
(Fig. 2C), as expected because PKC is the main kinase activated by bradykinin. The 
experiments in Fig 4 show that simple activation of PKC by a pro-inflammatory mediator 
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such as bradykinin is insufficient to cause sensitization of TRPV1. Formation of a scaffolding 
complex between TRPV1, AKAP79 and PKC is an essential pre-requisite for PKC to 
sensitize TRPV1.
A second important pro-inflammatory mediator is the prostaglandin PGE2, which 
sensitises TRPV1 in sensory neurons via both the Gq-coupled EP1 receptor and the Gs-
coupled EP4 receptor (Lopshire and Nicol, 1998; Southall and Vasko, 2001; Bhave et al., 
2002; Moriyama et al., 2005; Lin et al., 2006). We found that application of PGE2 to isolated 
rat sensory neurons caused a substantial sensitization, and as was the case with Bk, 
sensitisation by PGE2 was completely ablated by inclusion of the 14aa peptide which blocks 
the AKAP79/150 – TRPV1 interaction (Fig. 5A,B). Downregulating endogenous AKAP150 
by the use of siRNA had a similar inhibitory effect, and transfection of AKAP79 rescued the 
sensitization by PGE2. Interestingly, overexpression of AKAP79 did not produce a level of 
sensitization above that in untransfected neurons, in contrast to the enhanced sensitization 
seen with Bk. This difference is discussed further below.
In HEK293 cells co-expressing TRPV1 and the EP1 receptor, application of PGE2
caused significant sensitization (Fig. 5C, and see example traces in Supplementary Fig. 2A). 
Over-expression of AKAP79 enhanced sensitization (Fig. 5C, bar 3), which we attribute to a 
greater availability of the PKC binding site, an explanation which is reinforced by the similar 
enhancement observed when AKAP79 with the PKA site deleted was expressed (Fig. 5C, bar 
4). Sensitization was abolished, however, by expression of AKAP79 with the PKC site 
deleted, or by downregulation of endogenous AKAP79 by the use of siRNA (Fig. 5C, bars 5, 
6). These results show that sensitization of TRPV1 via the EP1 receptor is completely 
dependent on the presence of AKAP79 containing a PKC binding site. 
The results above show that PKC is able to phosphorylate TRPV1 only when 
AKAP79/150 is available to position the kinase appropriately. We also demonstrated this 
directly by the use of a phospho-serine antibody (Supplementary Fig. 1B). Serine 
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phosphorylation was enhanced when PKC was activated with PMA, but when endogenous 
AKAP79 was eliminated by transfection of siRNA the effect of PKC activation was 
abolished. 
In HEK293 cells transfected with the EP4 receptor we found that sensitization was 
abolished by deletion of the PKA binding site on AKAP79, or by down-regulation of 
endogenous AKAP79 by the use of siRNA, while deletion of the PKC site was without 
significant effect (Fig. 5 D, and see example traces in Supplementary Fig. 2B). These results 
show that sensitization via the EP4 receptor depends on the presence of AKAP79 containing a 
functional PKA binding site.
An interesting difference between Fig. 5C and D, which is also mirrored in the 
experiments on DRG neurons in Figs. 4B and 5B, is that sensitization via the PKC pathway is 
enhanced when AKAP79/150 is overexpressed, but sensitization via the PKA pathway is 
already maximal with endogenous levels of AKAP79/150. Thus endogenous levels of 
AKAP79/150 are not adequate to ensure full phosphorylation of TRPV1 when PKC is 
activated, and phosphorylation is boosted by transfection of further AKAP79/150, while 
endogenous levels of AKAP79/150 are adequate to ensure maximal  phosphorylation of 
TRPV1 following activation of PKA. 
NGF sensitizes TRPV1 mainly by causing increased trafficking to the surface 
membrane via a pathway involving the tyrosine kinase Src  (Zhang et al., 2005). Does this 
pathway also depend on AKAP79/150? Fig. 6A shows that NGF enhanced the membrane 
current activated by a near-saturating concentration of capsaicin, in agreement with previous 
studies  (Zhang et al., 2005; Stein et al., 2006). This effect is not, however, reduced by 
inclusion of the AKAP-TRPV1 blocking peptide in the pipette. We conclude that Src 
potentiates membrane trafficking of TRPV1 via an AKAP79/150-independent mechanism.
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Involvement of AKAP79/150 in desensitization
AKAP79/150 contains a binding site for the calcium-dependent phosphatase 
calcineurin (PP2B)  (Coghlan et al., 1995; Klauck et al., 1996), suggesting that AKAP79/150 
could play a role in desensitization of TRPV1, which is partly mediated by calcineurin  
(Docherty et al., 1996; Koplas et al., 1997; Vellani et al., 2001). In Fig. 6C we investigated 
desensitization by applying a near-saturating conditioning dose of capsaicin, which evoked a 
large inward current and caused strong desensitization of the current evoked by a second 
capsaicin exposure. Note that in these experiments the magnitude of desensitization depends 
strongly on the preceding calcium influx  (Koplas et al., 1997) and therefore it is important to 
select cells in which the calcium influxes in response to the conditioning pulse are similar, 
particularly in view of the fact (see Fig. 7C and discussion below) that treatments such as 
upregulating AKAP79 by transfection, or downregulating it by the use of siRNA, modulate 
the maximum current amplitude. See legend to Fig. 6D for further details.
Desensitization was largely abolished by removal of external Ca (Fig. 6D, bar 2). Over-
expression of AKAP79 strongly enhanced desensitization, while downregulation of 
endogenous AKAP79 by the use of siRNA substantially reduced it (Fig. 6C, D bars 3,4). 
AKAP79 with either the PKA site or the PKC site deleted behaved similarly to WT AKAP79 
(Fig. 6D, bars 5,6) showing that these kinases are not involved in desensitization when not 
activated by exogenous stimuli. Deletion of the calcineurin binding site, on the other hand, 
substantially reduced desensitization compared to that observed with expression of WT 
AKAP79 (Fig. 6D, last bar). In similar experiments on sensory neurons, inclusion of the 14aa 
blocking peptide also reduced desensitisation (Fig. 6E, F). 
These results implicate the calcineurin binding site of AKAP79 in the process of 
calcium-dependent desensitization of TRPV1. We note, however, that while removal of 
extracellular calcium almost completely abolished desensitization, removing the involvement 
of AKAP79, by downregulating AKAP79 with siRNA, by deleting the calcineurin binding 
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site, or (in neurons) by preventing binding of AKAP79 to TRPV1 with the inhibitory peptide, 
reduced but did not abolish desensitization (see Fig. 6C-F). A likely explanation is that 
another Ca-dependent mechanism of desensitisation is also present, in addition to the 
calcineurin/AKAP79 pathway. One possibility is that calmodulin may mediate calcium-
dependent desensitization of TRPV1, either by activating CaM kinase  (Jung et al., 2004; 
Novakova-Tousova et al., 2007) or by direct binding to a site in the intracellular N-terminal 
domain (Lishko et al., 2007). 
AKAP79/150 mediates translocation of TRPV1 to the membrane
In Fig 7 we investigated a possible effect of AKAP79/150 on trafficking of TRPV1 to 
the membrane. We first measured membrane expression of TRPV1 using biotinylation of 
surface membrane proteins (Fig. 7A, B) or by expressing a functional TRPV1 in which an 
HA tag had been engineered into the third extracellular loop (Fig. 7H). We also obtained an 
independent measure of surface membrane TRPV1 from the maximal membrane current 
elicited by a saturating dose of capsaicin (Fig. 7C, D). With all three methods over-
expression of AKAP79 caused a robust increase in surface membrane TRPV1 expression. 
Downregulation of AKAP79 using siRNA reduced but did not eliminate membrane 
expression (Fig. 7C, D). Deletion of either the PKC or the PKA binding site on AKAP79 
largely negates the effect of AKAP79 in promoting translocation of TRPV1 to the membrane, 
while deletion of the PP2B binding site is without effect (Fig 7A-D). The PKA inhibitor H89 
negates the effect of AKAP79 on trafficking of TRPV1 to the membrane (Fig. 7G, last lane). 
Thus AKAP79-mediated phosphorylation of TRPV1 by both PKC and PKA is important in 
translocation of TRPV1 to the membrane. 
We next sought to identify the residues on TRPV1 whose phosphorylation by PKC or 
PKA promotes trafficking to the membrane. Mutating S502 abolished the enhanced 
membrane expression caused by over-expression of AKAP79 (Fig. 7E) or activation of PKA 
by forskolin (Fig. 7F). By contrast, mutation of the S117 residue, which has been implicated 
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in sensitization of TRPV1 by PKA (Bhave et al., 2002), does not inhibit AKAP79-dependent 
membrane trafficking (Fig. 7G). These experiments implicate phosphorylation of the S502 
site as the main mechanism by which AKAP79 mediates translocation of TRPV1 to the 
surface membrane.
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Discussion
The experiments reported here show that inflammatory mediators acting via PKA or 
PKC depend completely on AKAP79/150 to mediate their effects on TRPV1 (see summary 
diagram in Fig. 8). Two main mechanisms of sensitization have been identified in previous 
studies: an enhancement of gating of TRPV1 ion channels already in the membrane, and an 
increase in trafficking of TRPV1 to the membrane. 
In the first and best-studied mechanism, mediators such as PGE2 or bradykinin activate 
either PKA or PKCε, which phosphorylate TRPV1 and increase the probability of gating of 
the channel by a wide range of activators. In the present study we find that sensitization of 
channel gating depends on the ability of the relevant kinase to bind to AKAP79/150, and in 
turn on the ability of AKAP79/150 to bind to TRPV1. The observation that sensitization is 
abolished by disrupting either of these binding mechanisms, or by removal of AKAP79/150 
using siRNA, implies that these two kinases must be pre-assembled in a signalling complex 
with TRPV1 in order to have any effect, and thus that free PKA or PKCε are unable to 
phosphorylate TRPV1 to any significant extent. The fact that inhibiting binding or removing 
AKAP79/150 completely inhibits sensitization adds further evidence to show that other 
proposed mechanism of sensitization, such as depletion of membrane PIP2 following 
activation of PLC (Chuang et al., 2001; Prescott and Julius, 2003), do not make any 
significant contribution to sensitization of TRPV1.
AKAP79/150 is also involved in trafficking of TRPV1 to the surface membrane. 
Previous studies have shown that trafficking can be promoted by phosphorylation of TRPV1 
either by Src  (Zhang et al., 2005) or by PKC  (Morenilla-Palao et al., 2004). The first 
mechanism is insensitive to disruption of binding between AKAP79/150 and TRPV1, 
showing that Src does not depend on AKAP79/150 to assemble it into a signalling complex 
with TRPV1. The ability of PKC and PKA to enhance trafficking does, however, depend 
absolutely on the presence of functional AKAP79/150. We have shown that the main target 
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of both kinases in promoting trafficking is S502,a  residue which is also involved in the 
potentiation of channel gating  (Numazaki et al., 2002; Bhave et al., 2003).
We have concentrated mainly on the functional consequences of binding of 
AKAP79/150 to TRPV1, but we have also obtained biochemical evidence for interactions of 
AKAP79 with other members of the thermo-TRP family, in particular TRPV4, TRPM8 and 
TRPA1 (Fig. 2). The functional consequences of AKAP79 binding for the activation of these 
channels remains to be explored. 
We have identified a 14aa domain in the C-terminal domain of TRPV1 which mediates 
binding of AKAP79. Previous studies have found that AKAP79 binds diffusely to other 
proteins (Colledge et al., 2000), so the identification of a small binding domain is something 
of a surprise. We did not find any obviously homologous binding domains on other thermo-
TRPs, apart from an area of weak homology between residues 705 and 724 of the C-terminal 
domain of TRPA1, which suggests that AKAP79/150 binds to other thermo-TRP proteins at 
non-homologous domains. A second possibility is that different intermediary proteins are 
involved in the binding to other thermo-TRPs, as was found for the binding of AKAP79/150 
to the NMDA and AMPA receptors  (Colledge et al., 2000). 
The dependence of sensitization of TRPV1 on AKAP79/150 raises the possibility that 
disrupting binding may reverse heat hyperalgesia in vivo. The binding site of AKAP79/150 to 
TRPV1 may therefore prove to be an attractive target for the development of novel 
analgesics.
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Experimental Procedures
Methods were as described previously (Zhang et al., 2005) with the following 
exceptions. Binding site deletions in AKAP79 for PKC, PKA and PP2B were performed 
using overlapping PCR to remove regions identified by Hoshi et al (2005). AKAP79 and 
binding site deletion mutants were GFP-coupled so that successfully transfected cells could 
be identified for whole cell patch clamp experiments. AKAP79 and AKAP150 were 
downregulated by using siRNA constructs (Hoshi et al., 2005) but cloned into the GFP-
expressing vector GFP-pGSH1 (Gelantis Inc) so that transfected cells could be identified 
from their GFP fluorescence for patch-clamp studies. DRG neurons were transfected using 
the Amaxa Nucleofector  according to the manufacturer’s instructions. A peptide blocking 
the binding site between AKAP79 and TRPV1, and scrambled control peptide (see Fig. 2), 
were obtained from Sigma purified to 75% purity. 
Whole-cell patch clamp recordings were carried out at a holding potential of -60mV 
and at room temperature, as described previously  (Zhang et al., 2005), except for 
experiments in which activation of TRPV1 was explored as a function of membrane voltage 
(Fig 3), when the holding potential was 0mV.  External solution for DRG neuron experiments
contained 140mM NaCl, 4mM KCl, 10mM HEPES, 1.8mM CaCl2, 1mM MgCl2 and 5mM 
Glucose, pH 7.4, while for experiments with HEK293 cells (with the exception of those 
shown in Fig. 6) CaCl2 was replaced with 5mM EGTA to inhibit desensitization. For 
recording maximal current density (Fig. 7C), calcium free solution was used and [Na]o was 
reduced to30mM (substituted with choline chloride) in order to reduce the maximum 
membrane current amplitude, as described previously  (Zhang et al., 2005). For experiments 
using inhibitory peptide DRG neurons were dialysed with peptide-containing intracellular 
solution for 10 minutes before starting recording. 
We thank the following for the kind gifts of plasmids: hTRPV1, John Davis; hTRPV2, 
Francois Rassendren; mTRPV3, Mike Zhu and Mike Caterina; hTRPV4, David Cohen; 
rTRPM8, Felix Viana; mTRPA1, Ardem Patapoutian; hAKAP79, John Scott; hB2 receptor,  
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Tanya O’Neill. EP1 and EP4 receptors were from UMR cDNA Resources Centre. All data are 
presented as mean  SEM, and significance was tested using an unpaired t-test. 
Experimental procedures are described in more detail in Supplementary Material.
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Figure legends
Fig.1. AKAP150 is co-expressed with TRPV1 in sensory neurons
A. TRPV1 (left) and AKAP150 (centre) co-express in small (<25m dia) rat DRG neurons 
(merged image at right). The majority of TRPV1 is present in subcellular vesicles (Zhang et 
al., 2005). 91.1  1.7% of TRPV1-positive neurons express AKAP150 (n=352). Scale bar 
10m.
B. Immunoprecipitating TRPV1 from rat DRG neurons co-immunoprecipitates AKAP150 
(upper blot, right lane). A control experiment using rat IgG does not immunoprecipitate either 
TRPV1 or AKAP150.
C. AKAP150 can be downregulated in rat DRG neurons by the use of an siRNA against 
AKAP150. The vector chosen for the siRNA expression also co-expressed GFP so that 
successfully transfected neurons could be identified (left column). A scrambled siRNA had no 
effect on AKAP150 levels in successfully transfected neurons (top) but the siRNA against 
AKAP150 downregulated expression (middle; mean 12.1 ± 1.9% of untransfected neurons in 
same images, n=6). Lower pair of images compares the effect of siRNA in adjacent 
transfected and untransfected neurons. Scale bar 20m.
D. Similar experiment in which AKAP79 in HEK293 cells was downregulated to a mean value 
of 15.9 ± 2.6% of control (n=22) by the use of an siRNA against AKAP79. AKAP79 and 
siRNA against AKAP79 were simultaneously co-expressed. Scale bar 10m.
E. Western blot showing downregulation of AKAP79 in HEK293 cells by siRNA and lack of 
effect of scrambled siRNA. Mean downregulation was to 30.4 ± 2.5% of control (n=3), but 
note that this includes some untransfected cells (c. 20% of total). Bottom image shows same 
blot stripped and reprobed for  tubulin to check similar loading in each lane.
Fig. 2. AKAP79 binds to a region in the TRPV1 C terminal domain.
A. Members of the thermo-TRP family of ion channels co-immunoprecipitate AKAP79. 
TRP proteins were immuno-precipitated with an antibody to a V5 tag fused to the 
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TRP C-termini and association of co-transfected AKAP79 was probed as shown in 
top blot. Expression levels of TRP proteins were similar in all cases (middle blot, 
which is top blot stripped and reprobed), apart from the first lane in which no TRP 
was transfected. Note the double principal bands for most TRPs, due to the presence 
of glycosylated (mature) and non-glycosylated (immature) protein  (Jahnel et al., 
2001). The V5 antibody does not cross-react with any endogenous HEK293 cell 
proteins (see left lane, in which no TRP was transfected), and fainter bands of lower 
M.Wt. are due the presence of truncated versions of the V5-tagged TRPs. Lower blot 
of total cell lysate (TCL) shows that AKAP79 expression was similar in all lanes. 
B. Converse experiment to that shown in A; AKAP79 was immunoprecipitated and 
association with the TRP proteins shown at top was probed with the V5 antibody. 
Association of TRP proteins with AKAP79 in both A and B was in the order 
TRPV1TRPV4>TRPA1TRPM8 >TRPV2TRV3.  Note that endogenous AKAP79 
expressed in HEK293 cells (left lane, middle panel) precipitates TRPV1, though to a 
lesser extent, even in the absence of transfected AKAP79 (see top panel, weak band in 
left lane). 
C. Co-ip of TRPV1 and AKAP79 demonstrated without use of the V5 antibody. 
Immunoprecipitation with a TRPV1 antibody raised to the N-terminal (right lane) co-
ips AKAP79. 
D. GST-coupled fragments of the hTRPV1 N-terminal (residues 1-433), intracellular 
loop 1 (498-513), intracellular loop 2 (557-579) and C-terminal (681-839) were 
expressed in E.coli, purified and tested for their ability to co-ip AKAP79. Note that all 
residue numbering is for the hTRPV1 used in these experiments. Bottom image, from 
an independent run, shows Coomassie stain of similar gel to demonstrate that 
expression levels of GST-coupled constructs were similar in all lanes. Principal band 
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in each lane is the GST-coupled construct; other bands are bacterial proteins 
incompletely removed during purification. 
E. GST-coupled fragments of the hTRPV1 C-terminal domain (681-839) were truncated 
as shown (left) or internal regions were deleted (right) and were examined for ability 
to co-immunoprecipitate AKAP79. Bottom image at left shows GST-coupled 
fragments stained with Coomassie in an independent run; bottom image at right shows 
blot above stripped and reprobed for GST to demonstrate similar loading in all lanes.
F. A 14aa peptide of sequence KDDYRWCFRVDEVN, corresponding to residues 736-
749 of hTRPV1, displaces binding between AKAP79 and TRPV1 GST-coupled C-
terminal. A peptide with the same composition but with scrambled sequence 
VCEYDVFDRNDKWR is ineffective.
G. Inhibitory peptide (see F) displaces binding between intact TRPV1 and AKAP79, 
while scrambled peptide is ineffective. Peptide added at stated final concentrations 
directly to lysate of HEK293 cells transfected with TRPV1 and AKAP79.  
Fig. 3. AKAP79 promotes activation of TRPV1
A. Peak inward current as a function of capsaicin concentration (5s pulse) in HEK293 
cells transfected with hTRPV1. Control dose-response relation (black points and 
curve, K½ = 244nM, Hill coefficient 1.82) is sensitized, i.e. displaced to lower 
capsaicin concentrations with no change in Hill coefficient, by co-transfection with 
AKAP79 (red points and curve, K½ = 92nM), and desensitized by co-transfection with 
AKAP79 with the PKC binding site deleted (green points and curve, K½ = 634nM).  
Deletion of PKA binding site of AKAP79 (squares, K½ = 180nM, curve not shown) 
reduced sensitivity less than deletion of the PKC binding site, while deletion of the 
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calcineurin binding site was indistinguishable from WT AKAP79 (blue points, K½ = 
112nM, curve not shown).
B. Whole-cell voltage-clamp experiments on HEK293 cells. Voltage-clamp pulse 
protocol shown at left. Other traces show currents in cells transfected with hTRPV1 
and with transfected AKAP79 and/or exposed to PMA (1M) as indicated.
C. Activation of TRPV1 by membrane voltage. Points derived from traces shown in B, 
as detailed in Methods. Curves are Boltzmann functions best-fitted to experimental 
points (see Methods). 
D. Average values of V½ obtained in experiments such as those shown in B and C. 
Numbers of experiments for each bar are (from left) 14, 13, 43 and 20. Error bars 
show  SEM. Significance levels are **, p<0.01 and ***, p<0.001 with respect to 
TRPV1 alone; ###, p<0.001 with respect to TRPV1+AKAP79.
Fig. 4. AKAP79 mediates sensitization of TRPV1 by bradykinin
A. Whole-cell voltage clamp experiments on small (<25m dia) rat DRG neurons. From 
top: bradykinin causes potent sensitisation of inward current activated by a 
subsaturating pulse of capsaicin (100nM, 5s); inclusion of blocking peptide (200M) 
in the patch clamp pipette abolished sensitisation; downregulation of AKAP150 by 
the use of siRNA largely abolished sensitization; sensitization was rescued by co-
transfection of AKAP79, which is insensitive to the siRNA against AKAP150. These 
experiments were conducted in the presence of 1.8 mM external [Ca2+], so substantial 
desensitization is observed in response to successive applications of capsaicin 
following application of Bk. Note that almost all TRPV1-positive neurons also 
expressed B2 receptors for Bk, as shown from the observation that >90% of naïve 
neurons responding to capsaicin showed an enhancement of response following 
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exposure to Bk. The suppression of sensitization by the inhibitory peptide or siRNA 
cannot therefore be attributed to chance selection of neurons not expressing receptors 
for Bk.
B. Collected results of experiments similar to those in A. Bars show maximum amplitude 
of first response following application of Bk relative to last response before 
application.  Bradykinin caused sensitization (bar 2; *, p<0.05 compared to control, 
n=19). Inclusion of peptide abolished sensitization (bar 3; ###, p<0.001 compared to 
bar 2, n=23). Scrambled peptide was ineffective in reversing sensitisation by 
bradykinin (bar 4; *, p<0.05 compared to control, n=13). SiRNA against AKAP150 
largely abolished sensitization (bar 5; #, p<0.05 compared to bar 2, n=15) but this 
effect was not seen with scrambled siRNA (bar 6; *, p<0.05 compared to control, 
n=20). Abolition of sensitization following transfection with siRNA could be rescued 
by co-transfection of AKAP79, which is insensitive to the siRNA against AKAP150 
(bar 7; ##, p<0.01 compared to bar 2, n=22).
C. Whole-cell voltage clamp experiments on HEK293 cells transfected with TRPV1 and 
bradykinin B2 receptor. Bradykinin (1M) caused potent sensitisation of the inward 
current activated by a subsaturating pulse of capsaicin (20nM, 5s). Sensitization was 
abolished by co-transfection of AKAP79 with the PKC binding site deleted, which 
has a dominant negative effect, or by down-regulation of endogenous AKAP79 
expression with siRNA. Note that these experiments were conducted in the absence of 
external Ca2+, which explains why desensitization is absent.
D. Collected results of experiments similar to those in C. Bradykinin caused potent 
sensitization (bar 2; ***, p<0.001 compared to control, n=25). Mutation of either or 
both target phosphorylation sites S502 and S801 to alanine largely abolished 
sensitization (bars 3-5, #, p<0.05 and ##, p<0.01 with respect to bar 2; n=5, 8 and 12). 
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Overexpressing AKAP79 causes enhanced sensitization (bar 6; #, p<0.05 compared to 
bar 2, n=16). Deleting the PKC binding site on AKAP79 largely abolishes 
sensitization (bar 7; ##, p<0.01 compared to bar 2, n=23). Deleting the PKA binding 
site is less effective (bar 8; not significant compared to bar 2, n=10). Sensitization is 
abolished by downregulating expression of AKAP79 by the use of siRNA (bar 9; ###, 
p<0.001 compared to bar 2, n=17). 
Fig. 5.  Sensitization by PGE2 is mediated by AKAP79/150
A. PGE2 causes potent sensitisation of inward current activated by a sub-saturating pulse 
of capsaicin (100nm, 5s) in small DRG neurons. From top: control neurons; blocking 
peptide (200M) included in the patch clamp pipette abolished sensitisation; 
downregulation of AKAP150 with siRNA largely abolished sensitization; 
sensitization was rescued by co-transfection of AKAP79. Break in trace is 10min 
period during which PGE2 was constantly perfused without application of capsaicin.
B. Collected results of experiments similar to those in A. PGE2 caused sensitization (bar 
2; *, p<0.05 compared to control, n= 9). Inclusion of peptide abolished sensitization 
(bar 3; ##, p<0.01 compared to bar 2, n=13). SiRNA against AKAP150 largely 
abolished sensitization (bar 4; ##, p<0.01 compared to bar 2, n=19). Abolition of 
sensitization following transfection with siRNA could be rescued by co-transfection 
of AKAP79 (bar 5; **, p<0.01 compared to control, n=11).
C. Collected results of whole-cell voltage clamp experiments on HEK293 cells 
transfected with TRPV1 and Gq-coupled prostaglandin EP1 receptor (see example 
traces in Supplementary Fig. 2A). PGE2 (1M) caused potent sensitization (bar 2; **, 
p<0.01 compared to control, n=27). Overexpressing AKAP79 causes enhanced 
sensitization (bar 3; ##, p<0.01 compared to bar 2, n=5). Deleting the PKA binding 
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site on AKAP79 has similar effect to WT AKAP79 (bar 4; ##, p<0.01 compared to 
bar 2, n=15). Deleting the PKC binding site abolishes sensitization (bar 5; #, p<0.05 
compared to bar 2, n=20). Sensitization is abolished by downregulating expression of 
AKAP79 by the use of siRNA (bar 6; #, p<0.05 compared to bar 2, n=13).  
D. Similar experiments in HEK293 cells transfected with the Gs-coupled EP4 receptor 
(see example traces in Supplementary Fig. 2B). PGE2 (1M) caused potent 
sensitization (bar 2; **, p<0.01 compared to control, n=13). Over-expressing 
AKAP79 does not further enhance sensitization (bar 3; ***, p<0.001 compared to 
control, n=6). Deleting the PKA binding site on AKAP79 abolishes sensitization (bar 
4; #, p<0.05 compared to bar 2, n=8). Deleting the PKC binding site has no effect on 
sensitization (bar 5; *, p<0.05 compared to control, n=10). Sensitization is abolished 
by down-regulating expression of AKAP79 by the use of siRNA (bar 6; ##, p<0.01 
compared to bar 2, n=7).
Fig. 6. AKAP79 partly mediates Ca-dependent desensitization of TRPV1 
A. AKAP79 does not mediate the sensitizing effects of NGF. From top: DRG neurons 
were exposed to near-saturating pulses of capsaicin (5s, 1M) separated by a 10min 
interval; application of NGF between pulses (100ng/ml, 10min) enhanced the inward 
current activated by capsaicin; the enhancement was not affected by inclusion of 
blocking peptide (200M) in the patch pipette.
B. Collected results of experiments similar to those in A. *, p<0.05; **, p<0.01 
compared to control (n=12,15,13).
C. Activation of TRPV1 by a near-saturating dose of capsaicin (1M, 5s) causes strong 
desensitization to a subsequent capsaicin application (top trace). Desensitization is 
enhanced by transfection of AKAP79 (middle trace), and is reduced but not abolished 
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by downregulation of AKAP79 with siRNA (lower trace).  Cells selected to have 
similar currents in response to conditioning application of capsaicin (see D).
D. Collected results of experiments similar to those in C. The magnitude of 
desensitisation depends on the amplitude of the preceding inward current through 
TRPV1 (Koplas et al., 1997), so to control for this potential source of variability data 
were only included from HEK293 cells with initial inward currents between 3.5 and 
5.5nA (i.e. current density between 100-200pA/pF). Desensitization is almost entirely 
Ca-dependent (bar 2; ***, p<0.001 compared to bar 1, n=12). Desensitization is 
enhanced by transfection of AKAP79 (bar 3; *, p<0.05 compared to bar 1, n=9) and is 
reduced but not abolished by downregulating AKAP79 with siRNA (bar 4; *, p<0.05 
compared to bar 1, n=8). Desenstization with PKA or PKC binding sites deleted is 
similar to WT AKAP (bars 5, 6; *, p<0.05, **, p<0.01 compared to bar 1, n=7,5), but 
desensitization is reduced by deletion of PP2 binding site (bar 7; not significant 
compared to bar 1, n=5).
E. Similar experiments in DRG neurons. Desensitization is reduced by inclusion of 
peptide in patch pipette.
F. Collected results of experiments on DRG neurons. Neurons selected with initial 
currents between 1.0 and 2.0nA. Significance level **, p<0.01 compared to first bar, 
n=19.
Fig. 7. AKAP79/150 promotes trafficking of TRPV1 to the cell surface membrane
A. Surface membrane expression of TRPV1 in HEK293 cells, measured by biotinylation 
of surface membrane TRPV1 in intact cells (Zhang et al., 2005), is promoted by 
transfection with AKAP79. The effect of AKAP79 transfection is inhibited by 
deletion of the PKA or PKC binding sites on AKAP79, but is not affected by deletion 
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of the PP2B (calcineurin) binding site. Lower image shows parallel experiment in 
which total TRPV1 was probed in total cell lysate to demonstrate constant loading of 
all lanes.
B. Mean band density obtained in 3 independent experiments. ***, p<0.001 compared to 
bar 1; ###, p<0.001 compared to bar 2.
C. Functional surface membrane expression of TRPV1 in HEK293 cells, measured in 
whole-cell voltage clamp experiments in HEK293 cells from maximal current elicited 
by a saturating dose of capsaicin (10M applied for 1s). Note that in these 
experiments the very large currents can cause loss of voltage clamp, and experiments 
were therefore carried out in [Na]o = 30mM (see Methods). Maximum current 
amplitude is increased by transfection of AKAP79 and is inhibited by downregulation 
of AKAP79 using siRNA. 
D. Mean results from experiments similar to C. Maximum current density is reduced by 
downregulation of endogenous AKAP79 using siRNA (bar 2; *, p<0.05 compared to 
bar 1; n=20). AKAP79 transfection enhances maximum current density (bar 3; **, 
p<0.01 compared to bar 1; n=42) but the effect is negated by PKA or PKC site 
deletions, but not by PP2B site deletion. Bar 4, #, p<0.05 compared to bar 3, n= 28; 
bar 5, #, p<0.05 compared to bar 3; bar 4, not significantly different from bar 3, n= 
24.
E. Enhancement of TRPV1 trafficking to the membrane by AKAP79 depends on the 
TRPV1 S502 site. Blots in E-G show surface membrane, obtained by biotinylation of 
intact HEK293 cells, and total TRPV1 as in A. The enhanced TRPV1 surface 
expression caused by co-transfection with AKAP79 is abolished by the S502A 
mutation. Mean band densities from left, relative to major band at top left: 1.0, 1.44, 
1.0, 1.03, n=3.
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F. Enhancement of TRPV1 trafficking to the membrane by PKA depends on the S502 
site. Forskolin (100M, 30 min) applied as shown to enhance PKA activity. Mean 
band densities from left, relative to major band at top left: 1.0, 2.11, 1.0, 0.86, n=3.
G. Mutation of the S117 site, which has also been shown to be a target for PKA  (Bhave 
et al., 2002), has no effect on enhancement of translocation of TRPV1 to the 
membrane caused by overexpression of AKAP79. Final lane shows that translocation 
caused by overexpression of AKA79 is partially PKA-dependent as it is inhibited by 
the PKA inhibitor H89 (1M for 30 minutes). Mean band densities from left, relative 
to major band at top left: 1.0, 1.66, 1.85, 1.01, n=2.
H. Surface membrane expression of TRPV1 in HEK293 cells, measured by 
immunoprecipitation of HA-tagged surface membrane TRPV1 in intact cells (see 
Methods), is promoted by overexpression of AKAP79. Mean band densities from left, 
relative to major band at top left: 1.0, 1.4, n=1.
Fig. 8. AKAP79/150 forms a signalling complex with TRPV1 
The scaffolding protein AKAP79/150 binds to a 14aa region in the C-terminal domain of the 
heat-activated ion channel TRPV1 (orange cylinder). The formation of this scaffolding 
complex aligns PKCε, the phosphatase calcineurin (PP2B) and PKA so as to control 
phosphorylation of key sites on TRPV1. The principal site involved in control of trafficking 
of TRPV1 to the membrane is S502. The tyrosine kinase Src can also promote trafficking to 
the membrane by phosphorylating Y200 (Zhang et al., 2005) but does so independently of 
AKAP79/150. TRPV1 has six ankyrin repeats in its N-terminal domain (Lishko et al., 2007). 
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